February 2018
Equiteq, the knowledge economy M&A specialist, is pleased to announce that it has advised Insight Strategy Advisors (ISA), a premier life sciences strategy consultancy, on its sale to Precision Value & Health, a part of Precision Medicine Group. ISA will become part of Precision Xtract, the global market access consultancy within Precision Value & Health.
Led by co-founders Harry Schiavi, President and CEO, and Stephen Reid, Managing Partner, ISA is a leading New York-based market access strategy consultancy supporting value proposition, pricing, reimbursement, and distribution for biopharmaceutical companies. Over its 15-year operating history, ISA has prospered into a world-class global market access consulting firm with a consistent track record of growth and long-tenured client relationships. The addition of ISA significantly enhances Precision Xtract’s existing strengths in market access strategy while strategically expanding expertise in quantitative pricing research, distribution, and contracting strategy. Leveraging existing analytics capabilities, the combination will also result in cutting-edge data harmonization and analytics offerings, guiding clients toward clinical and commercial success. “We are very excited to have the Insight Strategy Advisors team join Precision Xtract,” said Larry Blandford, Executive Vice President, Managing Partner of Precision Xtract. “Their team of specialists in market access deepens our ability to connect the critical elements of achieving global market access across evidence, economics, pricing, and access strategy. Moreover, we believe the combination will result in cutting-edge data harmonization and analytics that more precisely guide market access strategies.” Mr. Schiavi added, “Those two business factors, combined with how well our guiding principles align culturally, add to our enthusiasm about furthering global market access solutions as part of Precision.” Matt Hasson, Director of M&A in Equiteq’s New York office, commented, “Harry and Steve have developed ISA into an elite life sciences consultancy with an excellent market reputation, comprehensive market access capabilities, and talented human capital. These attributes, combined with strong industry fundamentals and an effective positioning strategy, engendered substantial interest from the buyer universe. I am thrilled that Equiteq was chosen as ISA’s financial advisor, and that we helped deliver a successful transaction outcome. I wish everyone at the company the best of luck as they embark on a new phase of growth under Precision’s ownership.” Regarding Equiteq’s role as exclusive advisor, Mr. Schiavi stated, “We selected Equiteq as our advisor primarily based on the firm’s strong M&A track record within the consulting industry, as well as its global reach. This proved to be the right decision as their expertise, experience, and guidance were critical to ensuring a successful transaction outcome. The Equiteq team was very well prepared and deftly handled both the details and the pacing of the transaction. I can’t imagine going through this process without Equiteq’s invaluable counsel.” Mr. Reid elaborated, “Equiteq built robust demand for our life sciences consulting firm, expertly communicating our value story to potential acquirers, while shepherding us through the partner evaluation process. Matt Hasson was a trusted advisor who helped maximize our valuation and whose dedication and tenacity got us to the finish line with the result that we were looking for.” Mr. Schiavi will join the Precision Xtract leadership team alongside Larry Blandford and Bruce Leavitt; Mr. Reid will continue in his role with a focus on overall business development. To see all of our deals, please click here. ©Equiteq 2018